204 related articles for article (PubMed ID: 21742296)
1. Liver fibrogenesis and metabolic factors.
Anty R; Lemoine M
Clin Res Hepatol Gastroenterol; 2011 Jun; 35 Suppl 1():S10-20. PubMed ID: 21742296
[TBL] [Abstract][Full Text] [Related]
2. Role of adipocytokines in hepatic fibrogenesis.
Ikejima K; Okumura K; Kon K; Takei Y; Sato N
J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S87-92. PubMed ID: 17567476
[TBL] [Abstract][Full Text] [Related]
3. A fresh look at NASH pathogenesis. Part 1: the metabolic movers.
Larter CZ; Chitturi S; Heydet D; Farrell GC
J Gastroenterol Hepatol; 2010 Apr; 25(4):672-90. PubMed ID: 20492324
[TBL] [Abstract][Full Text] [Related]
4. From the metabolic syndrome to NAFLD or vice versa?
Vanni E; Bugianesi E; Kotronen A; De Minicis S; Yki-Järvinen H; Svegliati-Baroni G
Dig Liver Dis; 2010 May; 42(5):320-30. PubMed ID: 20207596
[TBL] [Abstract][Full Text] [Related]
5. The metabolic syndrome: how it may influence hepatic stellate cell activation and hepatic fibrosis.
Lanthier N; Horsmans Y; Leclercq IA
Curr Opin Clin Nutr Metab Care; 2009 Jul; 12(4):404-11. PubMed ID: 19474722
[TBL] [Abstract][Full Text] [Related]
6. The evolving role of leptin and adiponectin in chronic liver diseases.
Tsochatzis E; Papatheodoridis GV; Archimandritis AJ
Am J Gastroenterol; 2006 Nov; 101(11):2629-40. PubMed ID: 16952281
[TBL] [Abstract][Full Text] [Related]
7. Dietary regulation of nuclear receptors in obesity-related metabolic syndrome.
Kawada T; Goto T; Hirai S; Kang MS; Uemura T; Yu R; Takahashi N
Asia Pac J Clin Nutr; 2008; 17 Suppl 1():126-30. PubMed ID: 18296319
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease.
Schäffler A; Schölmerich J; Büchler C
Nat Clin Pract Gastroenterol Hepatol; 2005 Jun; 2(6):273-80. PubMed ID: 16265231
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor-γ cross-regulation of signaling events implicated in liver fibrogenesis.
Zhang F; Lu Y; Zheng S
Cell Signal; 2012 Mar; 24(3):596-605. PubMed ID: 22108088
[TBL] [Abstract][Full Text] [Related]
10. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
Verna EC; Berk PD
Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of disease progression in nonalcoholic fatty liver disease.
Jou J; Choi SS; Diehl AM
Semin Liver Dis; 2008 Nov; 28(4):370-9. PubMed ID: 18956293
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro.
Yu J; Zhang S; Chu ES; Go MY; Lau RH; Zhao J; Wu CW; Tong L; Zhao J; Poon TC; Sung JJ
Int J Biochem Cell Biol; 2010 Jun; 42(6):948-57. PubMed ID: 20156580
[TBL] [Abstract][Full Text] [Related]
13. Fibrogenesis in nonalcoholic steatohepatitis.
De Minicis S; Svegliati-Baroni G
Expert Rev Gastroenterol Hepatol; 2011 Apr; 5(2):179-87. PubMed ID: 21476913
[TBL] [Abstract][Full Text] [Related]
14. Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH).
Krawczyk K; Szczesniak P; Kumor A; Jasinska A; Omulecka A; Pietruczuk M; Orszulak-Michalak D; Sporny S; Malecka-Panas E
J Physiol Pharmacol; 2009 Oct; 60 Suppl 3():71-5. PubMed ID: 19996485
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of hepatic fibrosis in non-alcoholic steatohepatitis.
Rombouts K; Marra F
Dig Dis; 2010; 28(1):229-35. PubMed ID: 20460917
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease.
Pettinelli P; Obregón AM; Videla LA
Nutr Hosp; 2011; 26(3):441-50. PubMed ID: 21892559
[TBL] [Abstract][Full Text] [Related]
17. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities.
Gambino R; Musso G; Cassader M
Antioxid Redox Signal; 2011 Sep; 15(5):1325-65. PubMed ID: 20969475
[TBL] [Abstract][Full Text] [Related]
18. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
[TBL] [Abstract][Full Text] [Related]
19. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease.
Polyzos SA; Kountouras J; Zavos C; Tsiaousi E
Diabetes Obes Metab; 2010 May; 12(5):365-83. PubMed ID: 20415685
[TBL] [Abstract][Full Text] [Related]
20. A novel agonist of PPAR-γ based on barbituric acid alleviates the development of non-alcoholic fatty liver disease by regulating adipocytokine expression and preventing insulin resistance.
Zheng H; Li S; Ma L; Cheng L; Deng C; Chen Z; Xie C; Xiang M; Jiang W; Chen L
Eur J Pharmacol; 2011 Jun; 659(2-3):244-51. PubMed ID: 21463618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
